Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CVM 
CEL-SCI Corp (CVM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: CVM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $180.01
1 Year Target Price $180.01
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 15.12% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 81.93M USD | Price to earnings Ratio - | 1Y Target Price 180.01 |
Price to earnings Ratio - | 1Y Target Price 180.01 | ||
Volume (30-day avg) 1 | Beta 0.55 | 52 Weeks Range 1.98 - 36.60 | Updated Date 09/14/2025 |
52 Weeks Range 1.98 - 36.60 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.13 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -70.09% | Return on Equity (TTM) -328.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 78713165 | Price to Sales(TTM) 11797.42 |
Enterprise Value 78713165 | Price to Sales(TTM) 11797.42 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.71 | Shares Outstanding 6882160 | Shares Floating 6318920 |
Shares Outstanding 6882160 | Shares Floating 6318920 | ||
Percent Insiders 8.18 | Percent Institutions 6.17 |
Upturn AI SWOT
CEL-SCI Corp
Company Overview
History and Background
CEL-SCI Corp was founded in 1983. It is a biotechnology company focused on researching and developing immunotherapy treatments for cancer and other diseases. Its primary focus has been on its investigational immunotherapy, Multikine.
Core Business Areas
- Oncology Immunotherapy: CEL-SCI is focused on the research and development of immunotherapy treatments for cancer. Their lead investigational product is Multikine (Leukocyte Interleukin, Injection), designed to boost the immune system to fight tumors.
Leadership and Structure
CEL-SCI's leadership team includes Geert Kersten (CEO), and other executives responsible for research, clinical trials, and finance. The company's structure is typical of a biotech firm, with departments dedicated to research and development, clinical operations, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- Multikine (Leukocyte Interleukin, Injection): Multikine is CEL-SCI's lead investigational immunotherapy treatment for head and neck cancer. As an investigational drug, it has no current market share. Competitors include pharmaceutical companies developing other cancer treatments and immunotherapies. Competitors include Merck (KEYTRUDA), Bristol Myers Squibb (OPDIVO), and other companies with approved cancer treatments.
Market Dynamics
Industry Overview
The oncology immunotherapy market is growing rapidly, driven by advancements in understanding the immune system's role in fighting cancer. There is high demand for innovative treatments with fewer side effects than traditional chemotherapy and radiation.
Positioning
CEL-SCI is a smaller biotech company attempting to compete with larger pharmaceutical companies in the oncology space. Their positioning depends heavily on the success of Multikine and its ability to demonstrate improved patient outcomes.
Total Addressable Market (TAM)
The global cancer immunotherapy market is estimated to reach hundreds of billions of dollars. CEL-SCI's position relative to the TAM depends on regulatory approval and market acceptance of Multikine. Given that Multikine is not yet approved and faces competition, CEL-SCI's share of the TAM is speculative.
Upturn SWOT Analysis
Strengths
- Proprietary immunotherapy technology (Multikine)
- Focus on head and neck cancer
- Dedicated research and development team
Weaknesses
- Dependence on a single product (Multikine)
- Limited financial resources compared to larger competitors
- Regulatory uncertainty
- History of clinical trial setbacks
Opportunities
- Potential for regulatory approval of Multikine
- Expansion into other cancer types
- Partnerships with larger pharmaceutical companies
- Advancements in immunotherapy research
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Patent expirations
- Fundraising challenges
Competitors and Market Share
Key Competitors
- MRK
- BMY
- PFE
Competitive Landscape
CEL-SCI faces significant competition from larger, more established pharmaceutical companies with greater resources and broader product portfolios. Its success hinges on differentiating Multikine and demonstrating superior clinical outcomes.
Growth Trajectory and Initiatives
Historical Growth: CEL-SCI's growth has been primarily in research and development, with no commercial revenue to date.
Future Projections: Future growth is dependent on the success of Multikine and potential regulatory approvals. Analyst projections vary widely based on assumptions about clinical trial outcomes and market adoption.
Recent Initiatives: Recent initiatives include efforts to complete clinical trials, secure regulatory approvals, and potentially partner with larger companies for commercialization.
Summary
CEL-SCI is a high-risk, high-reward biotechnology company. Its future hinges entirely on the success of Multikine in clinical trials and regulatory approval. While it has a promising technology, it faces significant competition and financial challenges and must be cautious about fundraising efforts.
Peer Comparison
Sources and Disclaimers
Data Sources:
- CEL-SCI Corp SEC filings (10-K, 10-Q)
- Financial news sources
- Biotechnology industry reports
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CEL-SCI Corp
Exchange NYSE MKT | Headquaters Vienna, VA, United States | ||
IPO Launch date 1987-01-01 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://cel-sci.com |
Full time employees - | Website https://cel-sci.com | ||
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.